Veliparib for the treatment of solid malignancies.

Objective: Veliparib is a poly adenosine diphosphate ribose polymerase (PARP) -1 and -2 inhibitor with chemo-sensitizing and anticancer activities that has shown promising results in early-phase trials. The aim of this comprehensive review is to summarise the profile of veliparib and to provide an overview of its early clinical investigations.

Data Sources: Details of all the completed trials evaluating the profile of veliparib were identified from ClinicalTrials.

Pre and Post-Operative Alterations of the Gastrointestinal Microbiome Following Bariatric Surgery.

Obesity in the United States is increasing at a startling rate, with more individuals turning towards bariatric surgery as treatment. A noteworthy aspect of obesity pathology is its interplay with the gastrointestinal microbiome. The gastrointestinal microbiome comprising trillions of microorganisms affects the dynamics of digestion, energy expenditure, and neurologic mechanisms that affect dietary preference.